¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Dent Res Grad Study"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® cohort study ÇÑ±Û °èȹ¿¬±¸, ÀüÇ⿬±¸, ¾Õ¹æÇ⿬±¸
¼³¸í   
  ºÐ¼®¿ªÇп¡¼­ÀÇ ¿äÀÎ-´ëÁ¶¿¬±¸ÀÇ ÇÑ ±â¹ýÀÌ´Ù. »ç¶÷ÀÇ Áý´Ü¿¡¼­ Áúº´À¯Çà°ú °¡¼³¿äÀΰúÀÇ ¿¬°ü¼ºÀ» °íÂûÇÏ¿© Àΰú°ü°è¸¦ ¹àÈ÷´Â °ÍÀ» ¸ñÀûÀ¸·Î ÇÑ´Ù. °¡¼³¿äÀÎÀ» °®´Â Áý´Ü°ú °®Áö ¾Ê´Â Áý´Ü, È¤Àº ÀûÀº Áý´Ü°ú ¸¹Àº Áý´ÜÀÇ 2±º(ÄÚȣƮ)À¸·Î ³ª´©¾î ÃßÀû Á¶»çÇÏ¿© °¢ Áý´Ü¿¡¼­ÀÇ Áúº´ÀÇ ¹ß»ýºóµµ¸¦ ºñ±³Çϴ °ÍÀÌ´Ù. ÀϹÝÀûÀ¸·Î´Â ÀüÇâÀûÀΠ¿¬±¸·Î ÇàÇØÁö´Â °æ¿ì°¡ ¸¹À¸³ª ÈÄÇâÀûÀΠ¿¬±¸·Îµµ ÇàÇÏ¿©Áø´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • air study
    °ø±âÁÖÀÔ°Ë»ç
  • cohort study
    ÄÚȣƮ¿¬±¸, ÄÚȣƮÁ¶»ç
  • controlled clinical study
    °ü¸®È­ÀÓ»ó½ÃÇè
  • crossover study
    ±³Â÷¿¬±¸
  • cross-sectional study
    ´Ü¸é¿¬±¸
  • case comparison study
    ȯÀÚ´ëÁ¶±º¿¬±¸
  • case referent study
    ȯÀÚ´ëÁ¶±º¿¬±¸
  • case study
    Áõ·Ê¿¬±¸, »ç·ÊÁ¶»ç
  • case-control study
    ȯÀÚ´ëÁ¶±º¿¬±¸, »ç·Ê´ëÁ¶±º¿¬±¸
  • diachronic study
    ºñµ¿½Ã¿¬±¸
  • double blind study
    ÀÌÁ߸Ͱ˿¬±¸
  • ecological study
    »ýÅ¿¬±¸
  • feasibility study
    °¡´É¼º¿¬±¸
  • follow-up study
    ÃßÀûÁ¶»ç
  • family study
    °¡Á·Á¶»ç
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • study design
    ¿¬±¸¼³°è
  • study
    ¿¬±¸, °Ë»ç, Á¶»ç
  • arterial blood gas study
    µ¿¸ÆÇ÷°¡½ººÐ¼®
  • case-control study
    ȯÀÚ´ëÁ¶±º¿¬±¸
  • cohort study
    ÄÚȣƮ¿¬±¸
  • cross-sectional study
    ´Ü¸éÁ¶»ç¿¬±¸
  • ecological study
    »ýÅ¿¬±¸
  • longitudinal study
    ÃßÀû¿¬±¸
  • observational study
    °üÂû¿¬±¸
  • pilot study
    ¿¹ºñ¿¬±¸
  • population study
    Àα¸Á¶»ç
  • prospective study
    ÀüÇ⿬±¸, °èȹ¿¬±¸, ¾Õ¹æÇ⿬±¸, Àü¸Á¿¬±¸
  • prospective cohort study
    ÀüÇâÄÚȣƮ¿¬±¸
  • retrospective study
    ÈÄÇ⿬±¸, µÞ¹æÇ⿬±¸, ȸ°í¿¬±¸
  • retrospective cohort study
    ÈÄÇâÄÚȣƮ¿¬±¸
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • air study
    °ø±âÁÖÀÔ°Ë»ç
  • arterial blood gas study
    µ¿¸ÆÇ÷°¡½ººÐ¼®
  • cardiac gated MR study
    ½ÉÀ嵿±âÀÚ±â°ø¸í°Ë»ç
  • case study
    Áõ·Ê¿¬±¸
  • case comparison study
    ȯÀÚ´ëÁ¶±º¿¬±¸
  • case compeer study
    ȯÀÚ´ëÁ¶±º¿¬±¸
  • case referent study
    ȯÀÚ´ëÁ¶±º¿¬±¸
  • case-base study
    ȯÀÚ¸ðÁý´Ü¿¬±¸
  • case-control study
    (¢¡retrospective) ÈÄÇ⿬±¸, µÞ¹æÇ⿬±¸
  • cohort study
    (¢¡prospective) °èȹ¿¬±¸, ÀüÇ⿬±¸, ¾Õ¹æÇ⿬±¸
  • controlled clinical study
    °ü¸®È­ÀÓ»ó½ÃÇè
  • cross-sectional study
    ´Ü¸éÁ¶»ç¿¬±¸
  • double-blind study
    ÀÌÁ߸Ͱ˹ý
  • study design
    ¿¬±¸°èȹ
  • family study
    °¡Á·Á¶»ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • RES=£¾reticuloendothelial system
    ¼¼¸Á³»Çǰ³, ¸Á³»°è.
  • B cell study
    B ¼¼Æ÷°Ë»ç
  • air study
    °ø±â(ÁÖÀÔ) °Ë»ç(¹ý)
  • arterial blood gas study
    µ¿¸ÆÇ÷ °¡½ººÐ¼®
  • infection control study
    °¨¿°°ü¸®¿¬±¸
  • phase 1 study
    ÀÓ»óÁ¦1»ó½ÃÇè.
  • pilot study
    ¿¹ºñ½ÇÇè.
  • population study
    Àα¸Á¶»ç
  • preclinical study
    ÀüÀÓ»ó½ÃÇè(îñìúßÉãËúÐ).
  • pressure flow study
    ¾Ð·ù·® Á¶»ç
  • pressure-perfusion study
    ¾Ð·Â°ü·ù°Ë»ç
  • prospective study
    °èȹÀû¿¬±¸, ÀüÇâÀû¿¬±¸
  • real time study
    ½Ç½Ã°£ °Ë»ç
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • disease, M ni res
    ¸Þ´Ï¿¡¸£º´
  • reticuloendothelial system =res
    ¼¼¸Á³»Çǰè(á¬ØÑÒ®ù«Í§), ¸Á³»°è(ØÑҮͧ)
  • syndrome, M{0e9}ni{0e8}res
    ¸Þ´Ï¿¡¸£ÁõÈıº
  • air study
    °ø±â(ÁÖÀÔ) °Ë»ç(¹ý)
  • arterial blood gas study
    µ¿¸ÆÇ÷ °¡½ººÐ¼®
  • cardiac gated MR study
    ½ÉÀ嵿±â ÀÚ±â°ø¸í °Ë»ç
  • case control study
    ȯÀÚ´ëÁ¶¿¬±¸.
  • case study
    Áõ·Ê¿¬±¸(Áõ¿¹¿¬±¸).
  • case study
    Áõ·Ê¿¬±¸(ñøçÓæÚϼ).
  • cohort study
    ÄÚ¿ÀÆ®¿¬±¸(ÊÙËçË´), Æø·ÎºñÆø·Î¿¬±¸.
  • controlled clinical study
    (Ãß°èÇÐÀû) °ü¸®È­(Ì§Ë­Ì°ËøË´ËöÌ´)(ÀÓ»ó)½ÃÇè( ËöË×ËàÌ´).
  • double-blind study
    ÀÌÁ߸ͰË.
  • family study
    °¡Á·Á¶»ç(¿¬±¸)
  • first pass study
    ÀÏÂ÷Åë°ú°Ë»ç.
  • follow-up study
    ÃßÀûÁ¶»ç
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • blance study
    ±ÕÇü¿¬±¸(гû¬æÚϼ)
  • RES
    (å²) Reticuloendothelial system
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • air study
    °ø±â(ÁÖÀÔ)°Ë»ç(¹ý)
  • cardiac gated MR study
    ½ÉÀ嵿±âÀÚ±â°ø¸í°Ë»ç
  • pilot study
    ¿¹ºñ½ÇÇè
  • prospective study
    ÀüÇâÀû¿¬±¸
  • real time study
    ½Ç½Ã°£°Ë»ç
  • retrospective study
    ÈÄÇ⼺¿¬±¸
  • study of choice
    ÃÖ¼±ÀÇ °Ë»ç
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
Dent, dent dentistry, dentist, dental, dentition
grad gradient; gradually; graduate
DENT Dental Exposure Normalization Technique
RES Reticulo-Endothelial System
ol res oleoresin
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
RES Reserpine
RES Reticulo Endothelial System
Study 1 study
Study 2 study
Study A study
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • JrId: 6122
    JournalTitle: Dental research and graduate study.
    MedAbbr: Dent Res Grad Study
    ISSN:
    ESSN:
    IsoAbbr:
    NlmId: 376544
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • dent- µ¿ÀǾî=dento-. ÀÌ¿ÍÀÇ °ü°è¸¦ ³ªÅ¸³»´Â Á¢µÎ¾î.

    dentagra

    Ä¡Åë, ¹ßÄ¡ °âÀÚ
    1. ¹ßÄ¡¿ëÀÇ °âÀÚ ¶Ç´Â ½û±â. 2. Ä¡Åë.
  • air study
    °ø±â °Ë»ç, °ø±â ÁÖÀÔ °Ë»ç, °ø±â °Ë»ç¹ý, °ø±â ÁÖÀÔ °Ë»ç¹ý
  • arterial blood gas study
    µ¿¸ÆÇ÷ °³½º ºÐ¾Ð ÃøÁ¤
  • case control study
    ȯÀÚ ´ëÁ¶ ¿¬±¸
  • case study
    Áõ·Ê ¿¬±¸
  • coagulation study
    ÀÀ°í °Ë»ç
  • controlled clinical study
    °ü¸®È­ ½ÃÇè, °ü¸®È­ ÀÓ»ó ½ÃÇè, Ãß°èÇÐÀû °ü¸®È­ ½ÃÇè, Ãß°èÇÐÀû °ü¸®È­ ÀÓ»ó ½ÃÇè
  • cross-sectional study
    Ⱦ´Ü ¿¬±¸¹ý, Ⱦ´Ü Á¶»ç¹ý
  • double-blind study
    ÀÌÁß ¸Í°Ë ¿¬±¸
  • electroencephalographic study
    ³úÆÄ °Ë»ç
  • enzyme marker study
    È¿¼Ò Ç¥Áö ¿¬±¸
  • longitudinal study
    ´©³âÀû ¿¬±¸, Á¾Àû ¿¬±¸, Á¾´Ü ¿¬±¸¹ý
  • microbiologic study
    »ý¹°ÇÐÀû °Ë»ç
  • microinjection study
    ¹Ì¼¼ ÁÖ»ç ¿¬±¸
  • mounted study cast
    ºÎÂøµÈ Áø´Ü ¸ðÇü
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
RES <abbreviation> Reticuloendothelial system.
(05 Mar 2000)
dent 1. <prefix> Relating to the teeth or dentition, dental.
See: odonto-.
Origin: L. Dens, tooth
2. A slight depression, or small notch or hollow, made by a blow or by pressure; an indentation. "A blow that would have made a dent in a pound of butter." (De Quincey)
Origin: A variant of Dint.
Source: Websters Dictionary
(21 Jun 2000)
grad <abbreviation> L. Gradatim, by degrees, gradually.
(05 Mar 2000)
grad-shafranov equation <radiobiology> Reduced magnetohydrodynamic-equilibrium equation for an axisymmetric, toroidal plasma. (Similar reduced equations can be derived for the cases of helical symmetry and for the straight cylinder.)
Analytic and numerical studies of these equations are important in exploring potential plasma configurations. The lowest order force balance in the plasma is simply that the Lorentz force must be balanced by the pressure force. This balance, combined with Maxwell's equations, determines the equilibrium configuration of the magnetic field.
When the toroidal configuration is axisymmetric, and the equilibrium plasma flow is zero, the magnetic field may be written in terms of a stream function \psi that satisfies the Grad-Shafranov equation \Delta\psi = - \mu_0 R^2 p'(\psi) - FF'(\psi). Here p is the plasma pressure and f = R B_\phi. (R is the radial distance from the axis of the machine).
In an axisymmetric torus, in the absence of equilibrium plasma fluid flows, the magnetic field may be written in terms of a scalar potential. When the plasma is in equilibrium (forces balance and the plasma is stationary), this scalar potential obeys a non-linear elliptic equation known as the Grad-Shafranov equation.
(09 Oct 1997)
analytic study In epidemiology, a study designed to examine associations, commonly putative or hypothesised causal relationships; usually concerned with identifying or measuring the effects of risk factors or with the health effects of specific exposures.
(05 Mar 2000)
blinded study Clinical trials of drugs are often done blinded so that the patient does not know (is blinded as to) whether they are receiving the product being tested or the control/placebo to ensure that the results of a study are not affected by a possible placebo effect (by the power of suggestion).
(12 Dec 1998)
blind study A study in which the experimenter is unaware of which group is subject to which procedure.
(05 Mar 2000)
case-control study <epidemiology> A study in which the risk factors of people with a disease are compared with those without a disease.
It is an epidemiological method that begins by identifying persons with the disease or condition of interest (the cases) and compares their past history of exposure to identified or suspected risk factors with the past history of similar exposures among persons who resemble the cases but do not have the disease or condition of interest (the controls).
The relationship of an attribute to the disease can therefore be examined by comparing affected and non-affected individuals with regard to the frequency or levels of the attribute in each group.
(05 May 2002)
retrospective study <epidemiology> A study in which people are enrolled and then have their history of risks, infections or disease measured.
(05 Dec 1998)
rosenzweig picture-frustration study A projective test depicting cartoon-like characters in frustrating situations. The scoring of the subject's responses indicates the direction of hostility or aggression, that is, whether he blames himself, the other person, or the set of circumstances.
(12 Dec 1998)
cohort study A study using epidemiological methods, such as a clinical trial, in which a cohort with a particular attribute (e.g., smokers, recipients of a drug) is followed prospectively and compared for some outcome (e.g., disease, cure) with another cohort not possessing the attribute.
(05 Mar 2000)
pioped study <radiology> 251 patients with documented PE on pulmonary angiograms were given V/Q scans: 102 high probability, 105 intermediate probability, 39 low probability, 5 normal or near-normal
(12 Dec 1998)
multicenter study A controlled study executed by several cooperating institutions.
(12 Dec 1998)
multigeneration study Toxicity test in which at least 3 generations of the test organisms are exposed to the substance being assessed. Exposure is usually continuous.
Any medical study which follows a family of people through several generations.
(09 Oct 1997)
crossover study <statistics> A study that compares two or more treatments or interventions in which the subjects or patients, upon completion of the course of one treatment, are switched to another. Usually refers to a study in which the subject is switched from the experimental to the control procedure (or vice versa).
In the case of two treatments, a and b, half the subjects are randomly allocated to receive these in the order a, b and half to receive them in the order b, a.
A criticism of this design is that effects of the first treatment may carry over into the period when the second is given.
With this type of study, every patient serves as his or her own control.
(21 Jun 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • grad
    Á¹¾÷»ý
  • dent
    ¿òÇ« µé¾î°£ °÷; ¿òÇ« ÆÄÁö´Ù
  • dent
    ¿òÇ« ÆÒ °÷
  • RES
    reticuloendothelial system
  • in medias res
    »ç°ÇÀÇ Á߽ɿ¡¼­;»ç°Ç µµÁߺÎÅÍ
  • res
    ¹°;½Çü;¹°°Ç;»ç°Ç;Àç»ê
  • res adjudicata
    =RES JUDICATA
  • res gestae
    ÀÌ·ç¾îÁø ÀÏ;¾÷Àû;(¼Ò¼Û»ç°ÇÀÇ)ºÎ´ë»óȲ(Áõ°Å ´É·ÂÀ» °¡Áø Áß¿äÇÑ »ç½Ç)
  • res judicata
    ±â°á »ç°Ç
  • res.
    research;reserve(d);residence;resides;resigned;resistance;resolution
  • study
    °øºÎ,¼­Àç,Çаú,¹è¿ì´Ù,¿¬±¸ÇÏ´Ù
  • brown study
    ¸ÛÇÏ´Ï»ý°¢¿¡Àá±è
  • case study
    »ç·Ê¿¬±¸;ÄÉÀ̽º ½ºÅ͵ð M
  • desk study
    (¿µ)Ź»ó ¿¬±¸
  • feasibility study
    Ÿ´ç¼º Á¶»ç;¿¹ºñ Á¶»ç
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á